Regulus Therapeutics Inc  

(Public, NASDAQ:RGLS)   Watch this stock  
Find more results for RGLS
7.19
+0.11 (1.55%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.81 - 7.39
52 week 5.83 - 12.89
Open 7.16
Vol / Avg. 87,306.00/153,316.00
Mkt cap 311.58M
P/E     -
Div/yield     -
EPS -0.51
Shares 43.34M
Beta     -
Inst. own 34%
May 22, 2014
Regulus Therapeutics Inc Annual Shareholder Meeting - 12:00PM EDT - Add to calendar
May 12, 2014
Q1 2014 Regulus Therapeutics Inc Earnings Release (Estimated) Add to calendar
May 7, 2014
Regulus Therapeutics Inc at Deutsche Bank Healthcare Conference - 8:40AM EDT - Add to calendar
Apr 9, 2014
Regulus Therapeutics Inc at Needham Life Sciences Conference
Mar 5, 2014
Regulus Therapeutics Inc at Cowen Health Care Conference
Feb 27, 2014
Q4 2013 Regulus Therapeutics Inc Earnings Conference Call
Feb 27, 2014
Q4 2013 Regulus Therapeutics Inc Earnings Release
Feb 13, 2014
Regulus Therapeutics Inc at Leerink Swann Global Healthcare Conference
Feb 11, 2014
Regulus Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 10, 2014
Regulus Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference (Panel Discussion)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -35.33% -95.40%
Operating margin -37.04% -96.82%
EBITD margin - -83.82%
Return on average assets -6.09% -16.48%
Return on average equity -8.23% -24.00%
Employees 76 -
CDP Score - -

Address

Suite 210, 3545 John Hopkins Court
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regulus Therapeutics Inc., is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012, the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. Effective March 5, 2014, Sanofi SA of France acquired an undisclosed minority stake in Regulus Therapeutics Inc.

Officers and directors

Stelios B. Papadopoulos Ph.D. Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. President, Chief Executive Officer, Principal Financial and Accounting Officer, Director
Age: 55
Bio & Compensation  - Reuters
Neil W. Gibson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
David Szekeres Chief Business Officer and General Counsel
Bio & Compensation  - Reuters
John M. Maraganore Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Director
Age: 59
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
David Baltimore PhD Independent Director
Age: 75
Bio & Compensation  - Reuters
Bruce L. A. Carter Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters